QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
Phase 1 study to assess the safety, preliminary efficacy of CD19 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose in subjects with diffuse large B-cell lymphoma (DLBCL).
Diffuse Large B Cell Lymphoma|Large-cell Lymphoma|Lymphoma, B-Cell|Lymphoma
BIOLOGICAL: CD19 t-haNK
MTD or HTD and RP2D., Maximum tolerated dose or highest tested dose and recommended phase 2 dose., 1 year|Incidence of DLTs and treatment-emergent adverse events, Incidence of DLTs and treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0., 1 year|Clinically significant changes, Clinically significant changes in safety laboratory tests, physical examinations, electrocardiograms (ECGs), and vital signs, as determined by the physician and/or lab ranges., 1 year
Objective Response Rate (ORR), ORR in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and modified RECIST guidelines for immunotherapy trials (iRECIST)., 1 year|Progression-free Survival (PFS), Progression-free Survival (PFS) by RECIST Version 1.1 and iRECIST., 1 year|Overall Survival (OS), OS will be evaluated using Kaplan-Meier methods., 1 year
Phase 1 study to assess the safety, preliminary efficacy of CD19 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose in subjects with diffuse large B-cell lymphoma (DLBCL). The study will be conducted in 2 parts: part 1 will involve dose escalation and part 2 will involve expansion of the recommended phase 2 dose.